Michel Detheux Biography and Net Worth

CEO of iTeos Therapeutics

Michel has served as our Chief Executive Officer and a director since our inception. He previously served as a director at Ludwig Cancer Research from December 2010 to March 2012. Prior to that, Michel worked in various scientific and business development roles at Ogeda (f/k/a Euroscreen).

Michel holds a degree in biochemistry degree and a Ph.D. in Biochemistry from Université Catholique de Louvain and a business certificate from Solvay Business School.

What is Michel Detheux's net worth?: The estimated net worth of Michel Detheux is at least $218,508.16 as of April 18th, 2022. Dr. Detheux owns 26,263 shares of iTeos Therapeutics stock worth more than $218,508 as of November 23rd. This net worth approximation does not reflect any other investments that Dr. Detheux may own. Additionally, Dr. Detheux receives a salary of $1,040,000.00 as CEO at iTeos Therapeutics. Learn More about Michel Detheux's net worth.
How old is Michel Detheux?: Dr. Detheux is currently 57 years old. There are 4 older executives and no younger executives at iTeos Therapeutics. Learn More on Michel Detheux's age.
What is Michel Detheux's salary?: As the CEO of iTeos Therapeutics, Inc., Dr. Detheux earns $1,040,000.00 per year. Learn More on Michel Detheux's salary.
How do I contact Michel Detheux?: The corporate mailing address for Dr. Detheux and other iTeos Therapeutics executives is , , . iTeos Therapeutics can also be reached via phone at 339-217-0161 and via email at [email protected]. Learn More on Michel Detheux's contact information.
Has Michel Detheux been buying or selling shares of iTeos Therapeutics?: Michel Detheux has not been actively trading shares of iTeos Therapeutics over the course of the past ninety days. Most recently, Michel Detheux sold 11,500 shares of the business's stock in a transaction on Monday, April 18th. The shares were sold at an average price of $31.87, for a transaction totalling $366,505.00. Following the completion of the sale, the chief executive officer now directly owns 26,263 shares of the company's stock, valued at $837,001.81. Learn More on Michel Detheux's trading history.
Who are iTeos Therapeutics' active insiders?: iTeos Therapeutics' insider roster includes Detlev Biniszkiewicz (Director), Michel Detheux (CEO), Ansbert Gadicke (Major Shareholder), Matthew Gall (CFO), David Hallal (Director), Les Korsh (VP), Joanne Lager (Insider), and Yvonne McGrath (VP). Learn More on iTeos Therapeutics' active insiders.
Are insiders buying or selling shares of iTeos Therapeutics?: During the last year, iTeos Therapeutics insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $38,650.00. The most recent insider tranaction occured on November, 19th when CFO Matthew Gall bought 5,000 shares worth more than $38,650.00. Insiders at iTeos Therapeutics own 12.5% of the company. Learn More about insider trades at iTeos Therapeutics.
Information on this page was last updated on 11/19/2024.

Michel Detheux Insider Trading History at iTeos Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/18/2022	Sell	11,500	$31.87	$366,505.00	26,263
3/22/2022	Sell	18,437	$34.17	$629,992.29
2/23/2022	Sell	14,500	$34.34	$497,930.00
1/25/2022	Sell	14,500	$35.68	$517,360.00
12/22/2021	Sell	16,163	$45.03	$727,819.89
12/20/2021	Sell	9,111	$43.94	$400,337.34
11/23/2021	Sell	14,500	$36.08	$523,160.00
11/3/2021	Sell	6,085	$28.89	$175,795.65
11/1/2021	Sell	81	$28.00	$2,268.00
10/21/2021	Sell	196	$28.00	$5,488.00
10/19/2021	Sell	201	$28.00	$5,628.00
10/15/2021	Sell	1,635	$28.01	$45,796.35
9/23/2021	Sell	5,322	$28.16	$149,867.52
9/1/2021	Sell	8,684	$28.30	$245,757.20
8/30/2021	Sell	2,322	$28.01	$65,039.22	132,104
8/27/2021	Sell	8,248	$28.17	$232,346.16
8/25/2021	Sell	861	$28.00	$24,108.00
8/23/2021	Sell	7,499	$28.06	$210,421.94	141,438
6/14/2021	Sell	29,000	$28.50	$826,500.00	152,874

Michel Detheux Buying and Selling Activity at iTeos Therapeutics

iTeos Therapeutics Company Overview

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $8.32

$8.05

$8.46

50 Day Range

MA: $9.45

$7.85

$12.12

2 Week Range

Now: $8.32

$7.54

$18.75

Volume

297,091 shs

Average Volume

444,601 shs

Market Capitalization

$303.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.

Michel Detheux Biography and Net Worth

What is Michel Detheux's net worth?

How old is Michel Detheux?

What is Michel Detheux's salary?

How do I contact Michel Detheux?

Has Michel Detheux been buying or selling shares of iTeos Therapeutics?

Who are iTeos Therapeutics' active insiders?

Are insiders buying or selling shares of iTeos Therapeutics?